Adding hydroxyurea to chronic transfusion therapy for sickle cell anemia reduces transfusion burden
Transfusion · 2025
DOI: 10.1111/trf.18073 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Transfusion, 2025. Verfasst von Robert Sheppard Nickel und 8 weiteren Autor:innen. Beteiligte Einrichtung: Children's National Hospital, Washington, DC, USA. Hauptthemen laut MEDLINE: Hydroxyurea, Anemia, Sickle Cell, Erythrocyte Transfusion, Antisickling Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, AABB Foundation, National Center for Advancing Translational Sciences.
Abstract (Originalsprache)
Background
Chronic red blood cell (RBC) transfusion is an established therapy to prevent stroke in patients with sickle cell anemia (SCA). It is unclear if adding daily hydroxyurea treatment to chronic transfusion is beneficial. Study Design and Methods We conducted a phase 2 clinical trial (NCT03644953) investigating the addition of dose‐escalated hydroxyurea to chronic transfusion for patients with SCA receiving simple chronic transfusion for stroke prevention. Simple chronic transfusion therapy was administered as per the same protocol before and after hydroxyurea treatment in which the volume transfused was dependent on the pretransfusion hemoglobin (Hb).
Results
A total of 14 participants enrolled with nine completing one year of combination hydroxyurea and transfusion (HAT) therapy after reaching hydroxyurea target dose. No participant who discontinued the study prematurely had a serious adverse event attributed to HAT. Among the nine participants who completed the study, eight participants achieved a reduction in RBC transfusion volume with a median reduction of −19.4 mL/kg/year (interquartile range −31.8, −2.8 mL/kg/year), p = .02, when comparing pre‐ and post‐HAT time periods. With the addition of hydroxyurea participants had a significant increase in pretransfusion Hb S% but this was balanced by an increased Hb F% and decreased lactate dehydrogenase. One participant developed a pretransfusion Hb >11 g/dL and Hb S > 45% that required holding hydroxyurea and changing to partial manual exchange transfusions. No patient had evidence of cerebrovascular disease progression.
Discussion
Hydroxyurea added to chronic transfusion therapy for patients with SCA is feasible and decreases RBC transfusion volume requirements.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Children's National Hospital, Washington, DC, USA.
- The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
- Children's National Research Institute, Washington, DC, USA.
ORCID-Profile: Robert Sheppard Nickel, Jennifer Webb
Förderung
- NCATS NIH HHS
- AABB Foundation
- National Center for Advancing Translational Sciences
Zitieren
APA
Nickel, R. S., Margulies, S., Panchapakesan, K., Chorvinsky, E., Nino, G., Gierdalski, M., Bost, J., Luban, N. L. C., & Webb, J. (2025). Adding hydroxyurea to chronic transfusion therapy for sickle cell anemia reduces transfusion burden. Transfusion. https://doi.org/10.1111/trf.18073
Vancouver
Nickel RS, Margulies S, Panchapakesan K, Chorvinsky E, Nino G, Gierdalski M, et al. Adding hydroxyurea to chronic transfusion therapy for sickle cell anemia reduces transfusion burden. Transfusion. 2025. doi:10.1111/trf.18073
BibTeX
@article{Nickel2025,
author = {Nickel, Robert Sheppard and Margulies, Stefanie and Panchapakesan, Karuna and Chorvinsky, Elizabeth and Nino, Gustavo and Gierdalski, Marcin and Bost, James and Luban, Naomi L C and Webb, Jennifer},
title = {Adding hydroxyurea to chronic transfusion therapy for sickle cell anemia reduces transfusion burden},
journal = {Transfusion},
year = {2025},
doi = {10.1111/trf.18073}
}
EUVIMED